期刊文献+

反义c-myc寡核苷酸对骨肉瘤细胞MG-63增殖的影响及机制 被引量:1

Effect of the c-myc antisense oligonucleotide on the proliferation of osteosarcoma cells(MG-63) and its mechanism
下载PDF
导出
摘要 目的探讨反义c-myc寡核苷酸对人骨肉瘤MG-63细胞增殖的影响及机制。方法采用反义核酸技术设计反义c-myc寡核苷酸片段,转染入人骨肉瘤MG-63细胞,MTT法及流式细胞仪法检测瘤细胞体外增殖、细胞周期及c-myc基因蛋白表达情况。结果MTT法示人骨肉瘤MG-63细胞的增殖受抑,10.0μmol/L、作用48 h效果最明显;流式细胞仪示反义c-myc寡核苷酸主要阻止人骨肉瘤MG-63细胞进入S期,c-myc基因蛋白表达受抑。结论反义c-myc寡核苷酸可抑制人骨肉瘤MG-63细胞的增殖;其机制为在基因水平干扰c-myc基因蛋白的表达。推测用反义策略抑制癌基因表达,或用基因敲除、基因替换的方法去除癌基因,可达到基因治疗的目的。 Objective To investigate the effect of the c-myc antisense oligonucleotide on the proliferation of osteosarcoma cells(MG-63) and its mechanism. Methods The c-myc antisense oligonucleotide fragment was designed by antisense oligonucleotide technique, and then transfected into human osteosarcoma MG-63 cell, the proliferation, cycle and c- myc protein expression of the cells were measured by MTr method and FCM method. Results The proliferation of human osteosarcoma MG-63 cell were inhibited by the c-myc antisense oligonucleotide, and the most notable effect was obtained when treated by the dosage of 10.0 μmol/L for forty-eight hours. The cycle of MG-63 cell into the S phase and the expression of c-myc protein were inhibited. Conclusions c-myc antisense oligonucleotide is able to inhibit the proliferation of human osteosareoma MG-63 cell, possible mechanism is interfere the expression of c-myc protein . Gene therapy can be used by inhibiting the expression of oncogene, or removing the oncogene by gene knock-out and gene replacement.
出处 《山东医药》 CAS 北大核心 2009年第19期1-3,共3页 Shandong Medical Journal
基金 贵州省教育厅自然科学研究基金资助项目(F2004-5)
关键词 寡核苷酸 反义 骨肉瘤 oligonucleotide, antisense osteosarcoma
  • 相关文献

参考文献6

二级参考文献8

共引文献37

同被引文献25

  • 1Mirabello L,Troisi RJ,Savage SA.Osteosarcoma incidence and survival rates from 1973 to 2004:data from the Surveillance,Epidemiology,and End Results Program[J].Cancer,2009,115(7):1531-1543.
  • 2Mialou V,Philip T,Kalifa C,et al.Metastatic osteosarcoma at diagnosis,prognostic factors and long-term outcome:the French pediatric experience[J].Cancer,2005,104(5):1100-1109.
  • 3Mankin HJ,Hornicek FJ,Rosenherg AE,et al.Survival data for 648 patients with osteosarcoma treated at one institution[J].Clin Orthop Relat Res,2004,420:286-291.
  • 4Kurzman ID,Shi F,Vail DM,et al.In vitro and in vivo enhancement of canine pulmonary alveolar macrophage cytotoxic activity against canine osteosarcoma cells[J].Cancer Biother Radiopharm,1999,14(2):121-128.
  • 5Ni J,Miller M,Stojanovic A,et al.Sustained effector function of IL-12/15/18 preactivated NK cells against established tumors[J].J Exp Med,2012,209(13):2351-2365.
  • 6Lin YM,Chang ZL,Liao YY,et al.IL-6 promotes ICAM-1 expression and cell motility in human osteosarcoma[J].Cancer Lett,2013,328(1):135-143.
  • 7Wang W,Song H,Liu J,et al.CD86+1057G/A polymorphism and susceptibility to osteosarcoma[J].DNA Cell Biol,2011,30(11):925-929.
  • 8Suminoe A,Matsuzaki A,Hattori H,et al.Immunotherapy with autologous dendritic cells and tumor antigens for children with refractory malignant solid tumors[J].Pediatr Transplant,2009,13(6):746-753.
  • 9Nagao H,Ijiri K,Hirotsu M,et al.Role of GLI2 in the growth of human osteosarcoma[J].J Pathol,2011,224(2):169-179.
  • 10Nakase M,Inui M,Okumura K,et al.p53 gene therapy of human osteosarcoma using a transferrin-modified cationic liposome[J].Mol Cancer Ther,2005,4(4):625-631.

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部